 |
 |
In a message dated 97-10-22 09:56:11 EDT, you write: I presume Dr. Olanow is speaking metaphorically- that there are elements of the action of selegiline that will lead to the discovery of "the ideal agent" not that the ideal agent is chemically in the current formulation. It certainly is unclear from your quote though. and << new work that they have done shows that Selegiline is metabolised to des-methyl selegiline and that entity is what provides the protective component >> Selegiline is a synthetic substance and if indeed the des-Me-selegiline is the bioactive metabolite doing the protective work, why not just provide the demethylated substance itself in a dosage form instead of making the body do the work? The bulk substance and the dosage forms of Selegiline was approved by the FDA around 1990. This means that the manufacturer had to prove the drug for efficacy as well as for other physical and chemical attributes. To that end, the manufacturer had to submit volumes of evidence. When additional evidence emerges, it becomes part of the drug submission. After approval of the NDA, the USP provides the specifications for the drug and then verifies that the products meets all these requirements. Michel M.